InvestorWire NewsRoom

Article

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference
August 5, 2021

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference

  • The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders
  • The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs
  • PFN’s development for its proprietary drug candidate, TRP-8803, focuses on increased efficacy, natural blood-brain barrier penetration, enhanced safety and toxicity profiles, reduced risk of abuse, and reduced risk of addiction

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a San Diego-based pharmaceuticals company, has joined the lineup of presenters at this year’s Canaccord Genuity Virtual Growth Conference, to be held virtually on August 10-12. Tryp is focused on developing psilocybin-based clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways (https://ibn.fm/gxu6h).

Tryp Chairman and CEO Greg McKee stated that the company would be presenting an overview of the business and its pipeline – including Tryp’s Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders. Tryp’s presentation will be held on August 10 at 3 p.m. EST. Register to view the presentation at https://ibn.fm/ja8ep.

Prior to this announcement, Tryp released a broadcast titled, “Psychedelics – Not Just for Mental Health Anymore,” highlighting the historical knowledge of psychedelics, such as peyote and psilocybin, and their healing effects, (https://ibn.fm/6c1sq). Modern-day research was hindered by the Controlled Substances Act of 1970, classifying psychedelics as Schedule I drugs with no medical use.

In the last few years, research has been lifting this stigma, including research done by Johns Hopkins Medical showing that two doses of psilocybin in combination with psychotherapy generated reduced symptoms for adults suffering from major depression. (can we link to the trial here). Many psychedelic companies have focused on depression, but Tryp is confident that psilocybin can effectively treat other underserviced indications, including chronic pain and certain eating disorders.

Tryp’s PFN program is focused on the development of psilocybin-based drug therapy for certain neuropsychiatric disorders. The psilocybin-based therapies have distinct advantages over other drugs currently on the market or in development, including:

  • Increased efficacy
  • Natural blood-brain barrier penetration
  • Enhanced safety and toxicity profiles
  • Reduced risk of abuse
  • Reduced risk of addiction

PFN features Tryp’s lead drug candidate, TRP-8802, with an initial indication of fibromyalgia. Tryp plans to seek FDA approval to proceed to Phase 2a clinical trials to evaluate the drug as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients found in TRP-8802.

So far in 2021, Tryp has achieved significant milestones, which include expanding its roster of world-class scientific advisors, initiating collaborations with world-renowned research institutions to advance clinical trials, advancing the manufacturing capability for synthetic psilocybin, and more. Tryp plans to continue achieving several other milestones before the end of 2021. These milestones include initiating at least two Phase 2a trials, announcing several new clinical research collaborations with leading academic research institutions, successful manufacturing and formulation of GMP synthetic psilocybin using proprietary methods, and filing for additional intellectual property applications.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).